SEARCH

SEARCH BY CITATION

References

  • 1
    Carter R, Colitz CMH. The causes, diagnosis and treatment of canine keratoconjunctivitis sicca. Veterinary Medicine 2002; 97: 683694.
  • 2
    Aguirre GD, Rubin LF, Harvey CE. Keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 1971; 158: 15661579.
  • 3
    Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Current Opinion in Ophthalmology 2004; 15: 299304.
  • 4
    Izci C, Celik I, Alkan F et al. Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca. American Journal of Veterinary Research 2002; 63: 688694.
  • 5
    Stern ME, Gao J, Siemasko KF et al. The role of lacrimal functional unit in the pathophysiology of the dry eye. Experimental Eye Research 2004; 78: 409416.
  • 6
    Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. Veterinary Clinics North America Small Animal Practice 1990; 20: 586613.
  • 7
    Olivero DK, Davidson MG, English RV et al. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 1991; 199: 10391042.
  • 8
    Tang-Liu DDS, Acheampong A. Ocular pharmacokinetics and safety of cyclosporine, a novel topical treatment for dry eye. Clinical Pharmacokinetics 2005; 44: 247261.
  • 9
    Calonge M. The treatment of dry eye. Survey of Ophthalmology 2011; 45: 2.
  • 10
    Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 219225.
  • 11
    Strong B, Farley W, Stern ME et al. Topical cyclosporine in inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005; 24: 8085.
  • 12
    Sahli E, Hosal BM, Zilelioglu G et al. The effect of topical cyclosporine A on clinical findings and cythological grade of the disease in patients with dry eye. Cornea 2010; 29: 14121416.
  • 13
    Baiza-Duran L, Pedrano-Palafox J, Hernandez-Quintela E et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. British Journal of Ophthalmology 2010; 94: 13121315.
  • 14
    Moore CP, McHugh JB, Thorne JG et al. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Investigative Ophthalmology & Visual Science 2001; 42: 3.
  • 15
    Diane D, Tang-Liu S, Acheampong A. Ocular pharmacokinetics and safety of cyclosporine, a novel topical treatment for dry eye. Clinical Pharmacokinetics 2005; 44: 247261.
  • 16
    Morgan R, Abrams K. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 1991; 199: 10431046.
  • 17
    Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114: 7679.
  • 18
    Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Survey of Ophthalmology 2009; 54: 3.
  • 19
    Sall K, Stevenson OD, Mundorf TK et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000; 107: 631639.
  • 20
    Wiener AL, Gilger BC. Advancements in ocular drug delivery. Veterinary Ophthalmology 2010; 13: 395406.
  • 21
    Davis JL, Gilger BC, Robinson MR. Novel approaches to ocular drug delivery. Current Opinion in Molecular Therapeutics 2004; 6: 195205.
  • 22
    Edelhauser HF, Rowe-Rendleman CL, Robinson MR et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Investigative Ophthalmology & Visual Science 2010; 51: 11.
  • 23
    Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicologic Pathology 2008; 36: 4962.
  • 24
    Lallemand F, Felt-Baeyens O, Besseghir K et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. European Journal of Pharmaceutics and Biopharmaceutics 2003; 56: 307318.
  • 25
    Italia JL, Bhardwaj V, Kumar MNVR. Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drug Discovery Today 2006; 11: 846854.
  • 26
    Gilger BC, Stoppini R, Wilkie DA et al. Treatment of immune-mediated keratitis in horses with episcleral silicone matrix cyclosporine delivery devices. Veterinary Ophthalmology 2014; 17: 2330.
  • 27
    Gilger BC, Salmon JH, Wilkie DA et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Investigative Ophthalmology and Visual Science 2006; 47: 25962605.
  • 28
    Gilger BC, Wilkie DA, Clode AB et al. Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Veterinary Ophthalmology 2010; 13: 294300.
  • 29
    Gilger BC, Salmon JH, Wilkie DA et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Investigative Ophthalmology & Visual Science 2006; 47: 6.
  • 30
    Ghosn CR, Li Y, Orilla WC et al. Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Investigative Ophthalmology & Visual Science 2011; 52: 6.
  • 31
    He Y, Liu Y, Liu Y et al. Cyclosporine-loaded microspheres for treatmentof uveitis. In vitro characterization and in vivo pharmacokinetic study. Investigative Ophthalmology & Visual Science 2006; 47: 9.
  • 32
    Kim H, Csaky KG, Gilger BC et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Investigative Ophthalmology & Visual Science 2005; 46: 2.
  • 33
    Kovacova Z, Balicki I, Trbolova A et al. Subconjunctival sustained-release cyclosporine implant in the treatment of chronic superficial keratitis in 8 German Shepherd dogs (abstract). Annual Scientific Meeting of the European College of Veterinary Ophthalmologists 2013; 116: E12.
  • 34
    Acton AE, Beale ABB, Gilger BC et al. Sustained release cyclosporine therapy for bilateral keratonojunctivitis sicca in a red wolf (canis rufus). Journal of Zoo and Animal Wildlife Medicine 2006; 37: 562564.
  • 35
    Rodriguez-Aller M, Kaufmann B, Guillarme D et al. In vivo characterisation of a novel water-soluble cyclosporine A prodrug for the treatment of dry eye disease. European Journal of Pharmaceutics and Biopharmaceutics 2012; 80: 544552.
  • 36
    Jiang J, Moore JS, Edelhauser HF et al. Intrascleral drug delivery to the eye using hollow microneedles. Pharmaceutica Research 2009; 26: 395403.
  • 37
    Hermans K, Van den Plas V, Everaert A et al. Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2012; 82: 2735.
  • 38
    Gupta C, Chauhan A. Ophthalmic delivery of cyclosporine A by punctal plugs. Journal of Controlled Release 2011; 150: 7076.
  • 39
    Nagarwal RC, Kant S, Singh PN et al. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. Journal of Controlled Release 2009; 136: 213.
  • 40
    Lee SS, Kim H, Wang NS et al. A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Investigative Ophthalmology & Visual Science 2007; 48: 5.
  • 41
    Acheampong AA, Shackleton M, Diane D-S et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Current Eye Research 1999; 18: 2.
  • 42
    Daull P, Lallemand F, Philips B et al. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea 2013; 32: 345354.